Journal of the American Academy of Dermatology
Volume 58, Issue 5 , Pages 781-786 , May 2008

Acne and oral contraceptives: Update on women's health screening guidelines

  • Jason E. Frangos, BA

      Affiliations

    • The Yale University School of Medicine, New Haven, Connecticut
    • ,
  • Christina N. Alavian, MD

      Affiliations

    • University of Massachusetts Medical School, Boston, Massachusetts
    • ,
  • Alexa B. Kimball, MD, MPH

      Affiliations

    • Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: Alexa B. Kimball, MD, MPH, Director, Clinical Unit for Research Trials in Skin, Massachusetts General Hospital, 50 Staniford St, #246 Dermatology, Boston, MA 02114.

,Accepted 28 December 2007.

References 

  1. Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651–663
  2. Redmond G, Olson W, Lippman J, Kafrissen M, Jones T, Jorizzo J. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89:615–622
  3. Lucky A, Henderson T, Olson W, Robisch D, Lebwohl M, Swinyer L. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997;37:746–754
  4. Maloney M, Marbit DI, Flack M, McLaughlin-Miley C, Sevilla C, Derman R. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Women's Health. 2001;(2):123
  5. Bayer HealthCare Pharmaceuticals . Yaz package insert. 2007;In press
  6. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2007;(1):CD004425
  7. American College of Obstetricians and Gynecologists . Oral contraceptives for adolescents: benefits and safety. Washington (DC): ACOG; 1999;
  8. Expert Working Group Meeting to Update the Selected Practice Recommendations for Contraceptive Use. Selected practice recommendations for contraceptive use. 2nd ed.. Geneva, Switzerland: World Health Organization; 2004;
  9. Faculty of Family Planning and Reproductive Health Care, Royal College of Obstetricians and Gynaecologists. First prescription of combined oral contraceptions: recommendations for clinical practice. Br J Fam Plann. 2000;26:27–38
  10. Society of Obstetricians and Gynaecologists of Canada. Canadian Contraception Consensus. Clinical practice guidelines No. 143- part 2. Available at: http://sogc.medical.org/guidelines/public/143E-CPG2-March2004.pdf. Accessed October 2007.
  11. IMAP statement on contraception for adolescents/young people in the era of HIV and AIDS. Available at: http://www.ippf.org/NR/rdonlyres/54B782C7-E761-4A76-8687-1A2B9D5C2CFB/0/IMAPstatementjune2006.pdf. Accessed October 2007.
  12. World Health Organization and U.S. Agency for International Development . Recommendations for updating selected practices in contraceptive use, volume I. Washington (DC): World Health Organization and U.S. Agency for International Development; 1994;
  13. Harper C, Balistreri E, Boggess J, Leon K, Darney P. Provision of hormonal contraceptives without a mandatory pelvic examination: the first stop demonstration project. Fam Plann Perspect. 2001;33:13–18
  14. Armstrong KA, Stover MA. SMART START: an option for adolescents to delay the pelvic examination and blood work in family planning clinics. J Adolesc Health. 1994;15:389–395
  15. Stewart FH, Harper CC, Ellertson CE, Grimes DA, Sawaya GF, Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence. JAMA. 2001;285:2232–2239
  16. Sawaya GF, McConnell KJ, Kulasingam SL, Lawson HW, Kerlikowske K, Melnikow J, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med. 2003;349:1501–1509
  17. Screening for squamous cervical cancer—the duration of low risk following negative results in cervical cytology test: Introduction. IARC Working Group on Cervical Cancer Screening. IARC Sci Publ. 1986;(76):15–24
  18. Padilla LA, Radosevich DM, Milad MP. Accuracy of the pelvic examination in detecting adnexal masses. Obstet Gynecol. 2000;96:593–598
  19. U.S. Preventive Services Task Force . Screening for ovarian cancer: recommendation statement. Ann Fam Med. 2004;2:260–262
  20. ACOG Committee on Gynecologic Practice. ACOG Committee Opinion No. 357: Primary and preventive care: periodic assessments. Obstet Gynecol. 2006;108:1615–1622
  21. American College of Obstetricians and Gynecologists. ACOG practice bulletin. cervical cytology screening. No. 45. Int J Gynaecol Obstet. 2003;83:237–247
  22. US Preventive Services Task Force. USPSTF screening for cervical cancer. Available at: http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.htm. Accessed October 2007.
  23. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. ACS guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342–362
  24. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579–1588
  25. FUTURE II Study Group . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927
  26. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369:1693–1702
  27. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24
  28. American College of Obstetricians and Gynecologists . ACOG practice bulletin. Clinical Management Guidelines for Obstetrician-gynecologists. No. 61, April 2005. Human papillomavirus. Obstet Gynecol. 2005;105:905–918
  29. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1–94
  30. US Preventive Services Task Force. Screening for gonorrhea: recommendation statement. 2005. Available at: http://www.ahrq.gov/clinic/uspstf05/gonorrhea/gonrs.htm. Accessed October 2007.
  31. U.S. Preventive Services Task Force . Screening for chlamydial infection: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2007;147:128–134
  32. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349:1443–1450
  33. ACOG Committee on Practice Bulletins-Gynecology . ACOG Practice Bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453–1472
  34. ACOG Committee on Practice Bulletins-Gynecology . ACOG practice bulletin. The use of hormonal contraception in women with coexisting medical conditions. Number 18. Int J Gynaecol Obstet. 2001;75:93–106
  35. World Health Organization . Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. 3rd ed.. Geneva, Switzerland: World Health Organization; 2003;
  36. Lewis M, Heinemann LJ, Spitzer W, MacRae K, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: results from the transnational study on oral contraceptives and the health of young women. Contraception. 1997;56:129–140
  37. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001;345:1787–1793
  38. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet. 1997;349:1202–1209
  39. Kemmeren JM, Tanis BC, vandenBosch MAAJ, Bollen ELEM, Helmerhorst FM, vanderGraaf Y, et al. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202–1208
  40. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet. 1996;348:498–505
  41. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer. 2001;95:370–374
  42. Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE study group. Steroid Hormones and Reproductions. Am J Epidemiol. 2000;152:233–241
  43. Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol. 2001;185(2 Suppl):S4–S12
  44. Rivera R, Almonte H, Arreola M, Lopez F, Monarrez G, Navarro C, et al. The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women. Contraception. 1983;27:311–327
  45. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000;96:913–920
  46. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001;10:561–569
  47. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006;95:385–389
  48. Moreno V, Bosch F, Muñoz N, Meijer C, Shah K, Walboomers J, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC Multicentric Case-control Study. Lancet. 2002;359:1085–1092
  49. Smith J, Green J, de Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361:1159–1167
  50. Saraiya M, Ahmed F, Krishnan S, Richards TB, Unger ER, Lawson HW. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol. 2007;109:360–370

 Funding sources: None.

 Disclosure: Dr Kimball is a consultant to Intendis. Mr Frangos and Dr Alavian have no conflicts of interest to declare.

PII: S0190-9622(08)00135-7

doi: 10.1016/j.jaad.2007.12.040

Journal of the American Academy of Dermatology
Volume 58, Issue 5 , Pages 781-786 , May 2008

Article Tools